As a new-type foreign trade service provider driven by technological transformation and export business, HiSiaddi has built a "1+2+3+4=1" service system and can supply wild yam extract and diosgenin sourced from multiple well-known original manufacturers.
Boasting R&D capabilities in technological transformation, HiSiaddi has conducted multiple rounds of factory inspections for wild yam extract and diosgenin manufacturers, maintaining objective and in-depth insights into different brands. We regularly analyze various domestic manufacturers of wild yam extract and diosgenin for clients to assist them in selecting matching products. Below is a brand selection recommendation case.
Contact HiSiaddi customer service for additional cross-brand and cross-model comparative analysis.
The purchasing party is BioBalance Healthcare Pty Ltd, Sydney, Australia, a leading mid-to-high-end domestic enterprise specializing in menopausal conditioning and phytosterol raw material R&D in Australia. Its full product line is sold in premium organic chain supermarkets nationwide, private gynecology clinics and high-end wellness hospitals across Australia. The brand enforces five mandatory access thresholds for raw material entry: Australian TGA drug regulatory standards, USP, FSMA import control, EU EC396 226-item pesticide residue testing and cGMP production specifications, rejecting feedstock from artificially cultivated yams and non-standard industrial-grade saponin raw materials.
Its core product lines include premium menopausal soft capsules and composite plant tablets, with diosgenin as the core efficacy raw material in formulations. Mandatory indicators: wild Qinba Dioscorea zingiberensis source, diosgenin content 98.0%±0.3%, split into two customized specifications: ultrafine powder for soft capsules and general powder for tablets. Annual planned stable procurement volume: 21 tons, with an 8-month scheduled new product launch timeline.
With over a decade of experience in terminal formulation development, the Australian enterprise previously sourced pharmaceutical-grade diosgenin long-term from Spain and India. Faced with rising overseas raw material prices and extended shipping cycles, it launched China-based sourcing in 2025. New to China’s plant extract industry, the client lacked full awareness of mainstream domestic diosgenin manufacturers, product models, process pros and cons, certification qualifications and dosage form compatibility. It successively contacted five leading domestic manufacturers via industry exhibitions and online channels: Shaanxi Hongda Bio, Chenggu Zhenhua Bio, Changsha Shanghe Bio, Xi’an Jiayuan Bio and Zhejiang Natural Bio. All five manufacturers maintained standardized business communication without deliberate slander of competitors, yet sales teams prioritized promoting their own products per performance targets, avoiding objective disclosure of peer product strengths and applicable scenarios while only sending self-branded samples.
The client received a total of 13 different diosgenin sample models from the five factories, sent batches to authoritative third-party Australian laboratories for testing and conducted small and pilot production trials at its in-house GMP formulation workshop. Multiple issues emerged including drastic content fluctuations, powder physical properties incompatible with filling lines, formulation discoloration triggered by raw material impurities and partial brands lacking compliance qualifications to meet Australian TGA access standards. Cumulative costs from sample testing, auxiliary material waste and production line debugging equaled 35,000 Australian dollars, delaying the new product launch timeline by 92 days. Unable to independently conduct horizontal comparisons of advantages and disadvantages across the five brands to accurately screen raw material models matching its formulation and production conditions, the client fully entrusted HiSiaddi Foreign Trade via referral from the Australian Natural Raw Materials Chamber of Commerce to conduct full-dimensional disassembly and evaluation of the five leading manufacturers as an impartial third party, screening 2 premium mid-to-high-end brands and 3 finalized product models aligned with the client’s formula and production conditions, coordinating sample re-verification and mass production delivery procurement.
HiSiaddi assembled a special research team consisting of plant extract raw material engineers, Australian regulatory consultants and powder testing specialists to conduct on-site visits to four production factories in Shaanxi, Hunan and Zhejiang. COA reports, factory compliance certifications and raw material traceability documents of each brand were retrieved, combined with measured test data to objectively organize the strengths, weaknesses and mainstream product models of the five leading manufacturers, eliminating information bias from unilateral factory marketing promotions.
Located in the raw material hinterland of the Qinba Mountains in Hanzhong, Shaanxi Province, the enterprise operates its own fixed harvesting cooperatives for wild Dioscorea zingiberensis with outstanding source raw material control capacity. Full export certifications including GMP, ISO22000, KOSHER and HALAL are in place, with long-term targeted supply of premium dietary pharmaceutical enterprises across Europe and America specializing in wild-source high-purity saponin.
Three mainstream product models:
1. HD-DIO98A: 98.0%±0.3% pharmaceutical-grade raw powder, standard 100 mesh, general tablet production grade, adopting enzymatic hydrolysis + recrystallization processes with low impurity content and stable cost performance;
2. HD-DIO98B: 98.0% ultrafine 200-mesh powder processed via low-temperature jet milling, customized exclusively for soft capsule filling with excellent powder flowability;
3. HD-DIO95: 95% purity cosmetic-grade saponin for external skincare products, not required for the client’s current procurement.
Brand Strengths: 100% wild Qinba Dioscorea zingiberensis raw material with zero cultivated yam adulteration, internal pesticide residue control standards stricter than EU EC396, and industry-leading batch content stability. Existing Weaknesses: Small-batch customized modification sample preparation cycle of 7~10 days, mid-to-high unit price among the five manufacturers, off-the-shelf inventory dominated by 98-series pharmaceutical-grade products with limited low-purity stock.
Founded over 30 years ago with an in-house API synthesis workshop, the enterprise leverages large-scale centralized procurement advantages in the Hanzhong production area with annual pharmaceutical-grade diosgenin output exceeding 100 tons, serving as a designated raw material supplier for multiple domestic listed pharmaceutical companies. Compliance systems align with both Chinese Pharmacopoeia and USP dual standards.
Mainstream Models:
1. ZH-98PH: Pharmacopoeia-grade 98% saponin, standard general powder with abundant large-batch off-the-shelf inventory;
2. ZH-95CO: 95% cosmetic-specific raw material.
Brand Strengths: Controllable costs via large-scale mass production, 10,000-ton warehouse inventory reserves and stable delivery cycles for bulk orders with strict internal solvent residue control. Existing Weaknesses: Mainly promotes standard particle size bulk powder; separate production line setup required for customized ultrafine 200-mesh powder, limited expertise in small-batch dosage-form-specific modification, approximately 75% wild raw material ratio supplemented with standardized cultivated yellow ginger feedstock leading to slightly lower maximum finished purity compared to Hongda.
Cooperated with Hunan Pharmaceutical Research Institute, specializing in high-purity plant monomers with complete SMB simulated moving bed chromatographic purification production lines, excelling in ultra-high-purity customized saponin above 98.5%, with exports primarily targeting high-end European and American pharmaceutical intermediates.
Mainstream Models: SH-DIO985 ultra-high-purity grade (98.5%±0.2%), SH-DIO98 general pharmaceutical powder. Brand Strengths: Leading purification technology with minimal impurity peaks in HPLC chromatograms and top-tier industry impurity control. Existing Weaknesses: Raw materials sourced externally from the Qinba production area without independent source harvesting control, occasional minor batch fluctuations in raw materials, highest product pricing among the five manufacturers, high minimum order thresholds unsuitable for the client’s regular mass production demand.
Specializes in niche customized extracts with flexible production lines capable of adjusting powder particle size and modification processes on demand, focusing on small and medium-batch foreign trade orders with complete food-grade and health supplement-grade product lines.
Mainstream Models: JY98-F food-grade 98% saponin, JY90 general feed-grade saponin. Brand Strengths: Low minimum order thresholds, expedited small-batch sample delivery and flexible modification processes. Existing Weaknesses: No proprietary wild raw material bases with externally sourced mixed cultivated yam feedstock leading to large fluctuations in active ingredient content per batch, incomplete full set of TGA and USP pharmaceutical factory-level certifications unable to fully meet Australian premium dietary access specifications.
Allocates fixed 8% of annual revenue to product R&D, specializing in raw material compatibility improvement with supporting auxiliary material pre-mixing laboratories, serving as a core supplier for East China health supplement factories.
Mainstream Models: ZT98-P tablet-specific saponin, ZT98-S general raw material powder. Brand Strengths: Comprehensive downstream formulation supporting services including simple auxiliary material debugging assistance for clients. Existing Weaknesses: All raw materials externally sourced with unstable wild yam supply, insufficient stability for continuous large-batch supply, internal pesticide residue control only meeting national standards without compliance with EU 226 full screening requirements.
Centered on the client’s three mandatory procurement criteria: compliance with Australian TGA + USP standards, 100% wild Qinba Dioscorea zingiberensis raw materials, compatibility with dual soft capsule and tablet production lines, and stable annual supply of 21 tons, HiSiaddi comprehensively eliminated Shanghe Bio (excessively high unit price, prohibitive minimum order thresholds), Jiayuan Bio (cultivated yam adulteration, incomplete compliance) and Zhejiang Natural Bio (unstable raw material supply, substandard pesticide residue control) by evaluating five dimensions: raw material sourcing, process technology, certifications, pricing and mass production stability. Two mid-to-high-end core supply brands – Shaanxi Hongda Bio and Chenggu Zhenhua Bio – were finalized, with three precisely matched product models selected to meet the production demands of the client’s two separate lines.
1. Hongda HD-DIO98B (200-mesh ultrafine 98% saponin): Exclusive soft capsule raw material processed via low-temperature nitrogen-sealed milling with a powder repose angle of 33°±2° and outstanding flowability, perfectly compatible with the client’s automatic soft capsule filling equipment to eliminate blockages and excessive filling weight deviation. Annual procurement volume: 12.3 tons as the client’s primary mass production grade.
2. Hongda HD-DIO98A (100-mesh national standard 98% raw powder): General tablet core raw material with wild yam feedstock and low impurity content, resisting oxidative discoloration when combined with the client’s vitamin C and mineral auxiliary materials to meet Australia’s 24-month tablet shelf-life stability requirements. Annual procurement volume: 5.2 tons.
3. Zhenhua ZH-98PH pharmacopoeia-grade 98% powder: Backup tablet supply model with abundant large-scale factory off-the-shelf inventory to serve as alternative supply during Hongda’s production capacity shortages, priced slightly lower than Hongda to balance overall procurement costs. Annual reserved procurement volume: 3.5 tons.
HiSiaddi coordinated both factories to send 3 parallel sample batches for each model in accordance with Australian TGA specifications, unified for full-item testing per USP and EC396 standards at SGS Australia laboratories. A full set of factory compliance certifications, raw material traceability ledgers, official origin harvesting certificates and bilingual English COA test reports were compiled to assist the client with pre-review of Australian importer filings.
Three rounds of samples passed all full-item physical, pesticide residue, heavy metal and solvent residue testing at Australian laboratories. 8 consecutive days of small-batch mass production trials at the client’s GMP workshop delivered soft capsule filling weight error controlled within ±1.9% and tablets free of browning or precipitation after 90 days of room-temperature storage, fully meeting new product launch standards. The first combined shipment of 6.8 tons of raw materials in separate specifications was nitrogen vacuum aluminum foil sealed and shipped from Shanghai Port to Sydney. Australian customs TGA documentation passed one-round pre-review for inspection-free smooth warehousing. Post raw material deployment, the client’s two new menopausal formulations successfully completed Australian drug regulatory filing and full rollout across premium pharmacies and organic supermarkets nationwide, with terminal sales in the first six months post-launch exceeding corporate planning by 27%.
Based on the successful brand selection delivery results, Australia’s BioBalance signed an annual locked-price procurement framework for 21 tons with HiSiaddi, split into 10 monthly production batches covering the three finalized products. The following year, the client expanded a premium hospital skincare product line with additional procurement demand for 95% specification diosgenin, once again entrusting HiSiaddi to conduct brand screening and sample coordination with priority retained cooperation from the two original suppliers. Backed by this mid-to-high-end Australian brand partnership, Hongda and Zhenhua optimized export graded product lines, subsequently securing equivalent saponin orders from three premium dietary brands in New Zealand and South Africa to steadily open a stable high-end natural extract supply chain across Oceania.
This full-service project clearly reveals widespread supply-demand information gaps in China’s diosgenin industry: even with benign competition without malicious peer slander, leading domestic plant extract manufacturers prioritize promoting their own product lines per sales performance targets while avoiding objective disclosure of competing brands’ product strengths, applicable scenarios and inherent weaknesses. This creates one-sided information for mid-to-high-end overseas clients conducting independent sourcing, who receive disjointed samples with chaotic indicators leading to misjudged brand selection, resulting in sample waste, delayed new product launches and substantial economic losses. Meanwhile, mid-to-high-end European, American and Australian dietary pharmaceutical brands possess in-depth expertise in terminal formulation R&D and local drug regulatory and production standards yet lack research channels covering China’s raw material origin resources, cross-factory process disparities and segmented application fields of various product models. Independent engagement with multiple factories easily leads to disjointed samples, confused indicators and misaligned selection triggering costly trial-and-error losses.
Drawing on years of industry databases and on-site research resources in plant extract foreign trade, HiSiaddi acts as an impartial third party breaking through marketing barriers of individual manufacturers to conduct horizontal benchmarking of full-dimensional parameters across five leading domestic brands. Centered on three core client demands: terminal formulation matching, production line equipment specifications and target market access regulations, brand and product model selection prioritizes raw material sourcing compliance, process compatibility, mass production stability and long-term supply security rather than pure low-cost orientation. The one-stop service helps mid-to-high-end overseas clients avoid various trade and production risks stemming from blind product selection. Simultaneously, objective impartial selection supports compliant high-capacity domestic manufacturers to escape low-price homogenization competition and steadily access the global high-end natural extract raw material supply chain via standardized pharmaceutical-grade products, delivering mutual long-term win-win outcomes for both Chinese and foreign supply and demand sides.
Contact HiSiaddi customer service for additional cross-brand and cross-model comparative analysis.
+86-13120989737 
info@hisiaddi.com 
English
